Nestlé to acquire remaining share of peanut allergy drug maker Aimmune for $2B
Nestle already owns a 25.6% stake in Aimmune worth $473 million, and the deal brings the total value of that investment to $2.6 billion. An analyst wrote that the deal's closing should be "smoother than a fresh jar of Skippy" and was not expected to meet antitrust or competitive hurdles.